S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.71 (-1.08%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.71 (-1.08%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.71 (-1.08%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.71 (-1.08%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
NASDAQ:ME

23andMe (ME) Stock Forecast, Price & News

$0.98
-0.10 (-8.97%)
(As of 12:39 PM ET)
Compare
Today's Range
$0.98
▼
$1.05
50-Day Range
$1.00
▼
$2.01
52-Week Range
$0.96
▼
$3.50
Volume
1.40 million shs
Average Volume
2.33 million shs
Market Capitalization
$464.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.92
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

23andMe MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
386.8% Upside
$4.92 Price Target
Short Interest
Bearish
8.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of 23andMe in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$403,610 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

675th out of 961 stocks

Pharmaceutical Preparations Industry

311th out of 454 stocks

See Top Rated MarketRank™ Stocks Here

ME stock logo

About 23andMe (NASDAQ:ME) Stock

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

ME Price History

ME Stock News Headlines

September 26, 2023 | americanbankingnews.com
23andMe Holding Co. (NASDAQ:ME) Insider Kathy L. Hibbs Sells 38,548 Shares of Stock
September 21, 2023 | msn.com
Reporter under investigation for stealing 2 'alien bodies' from Mexico
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 14, 2023 | msn.com
23andMe: Hidden Therapeutics Asset
September 14, 2023 | finance.yahoo.com
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
September 10, 2023 | msn.com
23andMe Is Too Far From Profitability
September 9, 2023 | theguardian.com
‘Something happened, somehow something got mixed up’: the at-home DNA test that changed two families for ever
September 6, 2023 | forbes.com
Lemonaid Review 2023: What You Need To Know
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 2, 2023 | msn.com
23andMe expands cancer at-home genetic report
September 2, 2023 | msn.com
Has anyone got a CRIgenetics, 23andMe, or Ancestry DNA test done?
September 1, 2023 | finance.yahoo.com
23andMe receives FDA approval to test for cancer variants
September 1, 2023 | msn.com
Wall Street Breakfast Podcast: 23andMe Receives New FDA Green Light
August 31, 2023 | msn.com
23andMe rises 17% on FDA clearance to report more genetic variants
August 31, 2023 | msn.com
23andMe stock rallies more than 23% after genetics company gets OK to report more cancer risks
August 31, 2023 | finance.yahoo.com
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
August 31, 2023 | benzinga.com
Global Direct-To-Consumer (DTC) Genetic Testing Market Size is Set to Forecast $22.3 Billion by 2030 | Genomic Exploration
August 25, 2023 | news.yahoo.com
Labor Day deals are here: $179 Roomba, Apple sale, Bose headphones, $100 off Apple Watch Ultra, more
August 22, 2023 | finance.yahoo.com
23andMe: DNA testing kit company needs drug discovery
August 19, 2023 | msn.com
Idaho murder case DNA issues raise questions about 23AndMe, Ancestry DNA: Robert Schalk
August 17, 2023 | forbes.com
AncestryDNA vs. 23andMe: Which Is Better?
August 11, 2023 | msn.com
DNA project collects over 2K samples from offenders, helps solve cold cases
August 11, 2023 | msn.com
Citigroup Maintains 23andMe Holding Co - (ME) Buy Recommendation
August 10, 2023 | markets.businessinsider.com
Citi Keeps Their Hold Rating on 23andMe Holding (ME)
August 9, 2023 | finance.yahoo.com
Why 23andMe Holding Stock Plummeted by 13% Today
August 9, 2023 | markets.businessinsider.com
Berenberg Bank Keeps Their Buy Rating on 23andMe Holding (ME)
August 9, 2023 | seekingalpha.com
23andMe down 3% on Q1 earnings, guidance revision
See More Headlines
Receive ME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter.

ME Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ME
CUSIP
N/A
CIK
1804591
Web
vgacquisition.com
Phone
650-938-6300
Fax
N/A
Employees
758
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.92
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$1.75
Forecasted Upside/Downside
+382.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-311,660,000.00
Net Margins
-110.45%
Pretax Margin
-111.30%
Return on Equity
-43.59%
Return on Assets
-33.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.03
Quick Ratio
2.93

Sales & Book Value

Annual Sales
$299.49 million
Price / Sales
1.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.55 per share
Price / Book
0.66

Miscellaneous

Outstanding Shares
472,490,000
Free Float
342,320,000
Market Cap
$481.94 million
Optionable
Not Optionable
Beta
1.42
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Ms. Anne Wojcicki
    Co-Founder, CEO, Pres & Chair of the Board
  • Mr. Joseph Selsavage (Age 60)
    Interim CFO & Accounting Officer
    Comp: $574.56k
  • Ms. Kathy L. Hibbs Esq. (Age 59)
    J.D., Chief Admin. Officer & Corp. Sec.
    Comp: $699.8k
  • Dr. Kenneth J. Hillan Ch.B. (Age 62)
    M.B., Exec. Officer
    Comp: $711.95k
  • Ms. Jacquie Cooke Haggarty J.D.
    Gen. Counsel & Privacy Officer
  • Ms. Katie Watson (Age 45)
    VP of Communications
  • Mr. Jonathan Ward
    Chief Marketing Officer
  • Mr. Reza Afkhami M.B.A.
    Chief Corp. Devel. Officer
  • Ms. Savita Pillai
    VP of People
  • Mr. David Baker (Age 52)
    Chief Security Officer & VP of Engineering

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ME Stock - Frequently Asked Questions

Should I buy or sell 23andMe stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ME shares.
View ME analyst ratings or view top-rated stocks.

What is 23andMe's stock price forecast for 2023?

3 Wall Street analysts have issued 12-month target prices for 23andMe's stock. Their ME share price forecasts range from $1.75 to $7.00. On average, they predict the company's share price to reach $4.92 in the next year. This suggests a possible upside of 382.0% from the stock's current price.
View analysts price targets for ME or view top-rated stocks among Wall Street analysts.

How have ME shares performed in 2023?

23andMe's stock was trading at $2.16 at the beginning of the year. Since then, ME shares have decreased by 52.8% and is now trading at $1.02.
View the best growth stocks for 2023 here.

When is 23andMe's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our ME earnings forecast.

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) announced its earnings results on Tuesday, August, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter. The firm had revenue of $60.86 million for the quarter, compared to analyst estimates of $56.90 million. 23andMe had a negative net margin of 110.45% and a negative trailing twelve-month return on equity of 43.59%.

What ETFs hold 23andMe's stock?

ETFs with the largest weight of 23andMe (NASDAQ:ME) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Global X Telemedicine & Digital Health ETF (EDOC).

What guidance has 23andMe issued on next quarter's earnings?

23andMe issued an update on its FY 2024 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $255.00 million-$275.00 million, compared to the consensus revenue estimate of $268.49 million.

What is 23andMe's stock symbol?

23andMe trades on the NASDAQ under the ticker symbol "ME."

Who are 23andMe's major shareholders?

23andMe's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.19%), State Street Corp (1.34%), Geode Capital Management LLC (1.22%), Renaissance Technologies LLC (0.54%), Northern Trust Corp (0.50%) and Charles Schwab Investment Management Inc. (0.46%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards.
View institutional ownership trends.

How do I buy shares of 23andMe?

Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 23andMe's stock price today?

One share of ME stock can currently be purchased for approximately $1.02.

How much money does 23andMe make?

23andMe (NASDAQ:ME) has a market capitalization of $481.94 million and generates $299.49 million in revenue each year. The company earns $-311,660,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How many employees does 23andMe have?

The company employs 758 workers across the globe.

How can I contact 23andMe?

23andMe's mailing address is 65 BLEECKER STREET 6TH FLOOR, NEW YORK NY, 10012. The official website for the company is vgacquisition.com. The company can be reached via phone at 650-938-6300 or via email at investors@23andme.com.

This page (NASDAQ:ME) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -